In a study published in Cell, a research team led by Zhu Shujia from the Center for Excellence in Brain Science and ...

The detailed mechanisms by which NMDA receptor activation and the subsequent ... would be activated synchronously by glutamate release from the same terminal? Is this a stable endpoint of synaptic ...

The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...

InFlectis BioScience SAS, a drug discovery company pioneering development of therapeutics harnessing the Integrated Stress ...

and amantadine (based on its effect as a noncompetitive inhibitor of the N-methyl-D-aspartate [NMDA]-sensitive ionotropic glutamate receptor). 3,8 As dextromethorphan is a substrate for CYP2D6 and ...

Like many other antidepressants, Spravato works as a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. Where it differs, however, is its ability to travel ...

Iclepertin – which regulates the concentration of glycine in the brain and in turn modulates the activity of NMDA receptors for the neurotransmitter glutamate – was one of two mental health ...